Status: Not yet recruiting
Sintilimab Monotherapy in Patients With Stage I-II MSI-H/dMMR Endometrial Cancer
To investigate the efficacy and safety of immune checkpoint inhibitors as a non-surgical (surgery-avoiding) treatment in patients with stage I-II MSI-H/dMMR endometrial cancer.
Participants needed: 48
Trial details
Phase: Phase 2Age: 18-75Biological sex: FemaleType: InterventionalSponsor: Wang JianliuUpdated: Jul 28, 2026
Eligibility criteria
Aged 18-75 years. [+8]
Presence of active autoimmune disease, or long-term requirement for immunosuppre... [+7]